Download PDF
Thromb Haemost 2002; 87(05): 802-807
DOI: 10.1055/s-0037-1613087
Review Article
Schattauer GmbH

Patients with Essential Thrombocythaemia have an Increased Prevalence of Antiphospholipid Antibodies which may be associated with Thrombosis

C.N. Harrison
1   Department of Haematology, University College London Hospital, UK
,
S. Donohoe
1   Department of Haematology, University College London Hospital, UK
,
P. Carr
1   Department of Haematology, University College London Hospital, UK
,
M. Dave
1   Department of Haematology, University College London Hospital, UK
,
I. Mackie
1   Department of Haematology, University College London Hospital, UK
,
S.J. Machin
1   Department of Haematology, University College London Hospital, UK
› Author Affiliations
Further Information

Publication History

Received 09 July 2001

Accepted after resubmission 04 February 2002

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

Summary

A significant proportion of patients with Essential Thrombocythaemia (ET) have thrombotic complications which have an important impact upon the quality, and duration of their life. We performed a retrospective cross sectional study of the prevalence of antiphospholipid antibodies (APA) in 68 ET patients. Compared to 200 “elderly” controls (> 50 years) there was a significant increase in anticardiolipin IgM (p < 0.0001) and anti β2 glycoprotein I (anti-β2GPI) IgM (p < 0.0001) antibodies in ET. Thrombosis occurred in 10/20 with APA and 12/48 without, p = 0.04, relative risk 2.0 (95% confidence intervals 1.03–3.86); these patients did not differ in terms of other clinical features. The prevalence of thrombosis in patients with dual APA (6/7) was significant when compared to those with single APA (p = 0.02) and the remaining patients (p < 0.0002). Also anti-β2GP1 IgM antibodies either alone, or in combination with another APA, were associated with thrombosis (p = 0.02). These results suggest that the prevalence of APA in ET and their influence upon thrombotic risk merit investigation in a larger study.

Keywords

ET - antiphospholipid antibodies - thrombosis
 

  • References

  • 1 Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-6.
    CrossrefPubMedGoogle Scholar
  • 2 Lengfelder E, Hochhaus A, Kronawitter U, Hoche D, Queisser W, Jahn-Eder M, Burkhardt R, Reiter A, Ansari H, Hehlmann R. Should a platelet limit of 600 X 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998; 100: 15-23.
    CrossrefPubMedGoogle Scholar
  • 3 Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616-22.
    PubMedGoogle Scholar
  • 4 Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 08: 556-62.
    CrossrefPubMedGoogle Scholar
  • 5 Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythaemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 93: 417-24.
    PubMedGoogle Scholar
  • 6 Chiusolo P, La Barbera EO, Laurenti L, Piccirillo N, Sora F, Giordano G, Urbano R, Mazzucconi MG, De Stefano V, Leone G, Sica S. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol 2001; 29: 670-6.
    CrossrefPubMedGoogle Scholar
  • 7 Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol 1993; 83: 192-7.
    CrossrefPubMedGoogle Scholar
  • 8 Harrison CN, Machin SJ. Essential thrombocythaemia and antiphospholipid antibodies. Am J Med 1997; 102: 317-8.
    CrossrefPubMedGoogle Scholar
  • 9 Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
    PubMedGoogle Scholar
  • 10 Petri M. Epidemiology of the antiphospholipid antibody. Journal of Autoimmunity 2000; 15: 145-51.
    CrossrefPubMedGoogle Scholar
  • 11 Scurr JH, Machin SJ, Bailey-Kig S, Mackie IJ, McDonald S, Smith PD. Frequency and prevention of symptomless deep-vein thrombosis in longhaul flights: a randomised trial. Lancet 2001; 357: 1485-9.
    CrossrefPubMedGoogle Scholar
  • 12 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-45.
    PubMedGoogle Scholar
  • 13 Harris EN, Hughes GR. Standardising the anti-cardiolipin antibody test. Lancet 1987; 01: 77.
    PubMedGoogle Scholar
  • 14 McNally T, Mackie IJ, Machin SJ, Isenberg DA. Increased levels of beta 2-glycoprotein-I antigen and beta 2-glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995; 34: 1031-6.
    CrossrefPubMedGoogle Scholar
  • 15 Donohoe S, Mackie IJ, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001; 113: 544-9.
    CrossrefPubMedGoogle Scholar
  • 16 Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome?. Journal of Autoimmunity 2000; 15: 163-72.
    CrossrefPubMedGoogle Scholar
  • 17 Horbach DA, Oort EV, Donders RCJM, Derksen RHWM, deGroot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with SLE. Thromb Haemost 1996; 76: 916-24.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Varaala O, Puurunen M, Manttari M, Manien V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle aged men. Thromb Haemost 1996; 75: 456-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D’Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
    CrossrefPubMedGoogle Scholar
  • 20 Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Zaccari G, Papa G. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma. Thromb Haemost 1993; 70: 568-72.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Stasi R, Stipa E, Masi M, Oliva F, Olivieri M, Perrotti A, Zaccari G, Amadori S, Papa G. Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma. Recenti Prog Med 1995; 86: 57-62.
    PubMedGoogle Scholar
  • 22 Crook M, Machin S, Crawford N. Electrokinetic behaviour and surface sialic acid status of blood platelets in essential thrombocythaemia (ET). Eur J Haematol 1992; 49: 128-32.
    PubMedGoogle Scholar
  • 23 Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Br J Haematol 2001; 115: 451-9.
    CrossrefPubMedGoogle Scholar
  • 24 Griesshammer M, Beneke H, Nussbaumer B, Grunewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res 1999; 96: 191-6.
    CrossrefPubMedGoogle Scholar
  • 25 Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001; 66: 143-51.
    CrossrefPubMedGoogle Scholar
  • 26 van Genderen PJ, Prins FJ, Michiels JJ, Schror K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol 1999; 104: 438-41.
    CrossrefPubMedGoogle Scholar
  • 27 Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythaemia and polycythemia vera. Blood 2000; 96: 4261-6.
    PubMedGoogle Scholar
  • 28 Hill MB, Phipps JL, Hughes P, Greaves M. Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes. Br J Haematol 1998; 103: 416-21.
    CrossrefPubMedGoogle Scholar
  • 29 Gharavi AE, Pierangeli SS. Infections and Antiphospholipid Antibodies. In: Khamashta M. (ed) 2000. Hughes Syndrome Antiphospholipid Syndrome. London: Springer-Verlag Limited; 135-43.
    Google Scholar
  • 30 Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-15.
    CrossrefPubMedGoogle Scholar